Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Regulatory
53 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Trastuzumab Deruxtecan | US FDA | Tumor-agnostic | HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. • HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options* • * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )accelerated | approved | Dec 20, 2019 | openfda |
| Vandetanib | EU EMA | Thyroid Gland Medullary Carcinoma | Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision. | approved | Feb 16, 2012 | ema |
| Vandetanib | US FDA | Thyroid Gland Medullary Carcinoma | CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. CAPRELSA is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. ( 1 ) Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. ( 1 ) | approved | Apr 6, 2011 | openfda |
Data updated 19 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Selpercatinib | 18 | 14 | 4 |
| Vemurafenib | 15 | 12 | 3 |
| Cetuximab | 13 | 7 | 6 |
| Dabrafenib | 11 | 11 | 0 |
| Trametinib | 10 | 10 | 0 |
| Erlotinib | 7 | 6 | 1 |
| Afatinib | 4 | 3 | 1 |
| Larotrectinib | 4 | 4 | 0 |
| Taselisib | 4 | 3 | 1 |
| Docetaxel | 3 | 1 | 2 |
| Fluorouracil | 3 | 3 | 0 |
| Pralsetinib | 3 | 0 | 3 |
| Radiation Therapy |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 3 |
| 2 |
| 1 |
| Aspirin | 2 | 2 | 0 |
| Axitinib | 2 | 0 | 2 |
| Cabozantinib | 2 | 2 | 0 |
| Cisplatin | 2 | 1 | 1 |
| Crizotinib | 2 | 2 | 0 |
| Dabrafenib/Trametinib Regimen | 2 | 2 | 0 |
| Dasatinib | 2 | 2 | 0 |
| Everolimus | 2 | 1 | 1 |
| JSI-124 | 2 | 2 | 0 |
| Lapatinib | 2 | 2 | 0 |
| Motesanib | 2 | 0 | 2 |
| Panitumumab | 2 | 1 | 1 |
| Pembrolizumab | 2 | 2 | 0 |
| Pertuzumab | 2 | 2 | 0 |
| Sulindac | 2 | 2 | 0 |
| Alectinib | 1 | 1 | 0 |
| Alisertib | 1 | 1 | 0 |
| Alpelisib | 1 | 0 | 1 |
| Apitolisib | 1 | 1 | 0 |
| Barasertib | 1 | 1 | 0 |
| Bimiralisib | 1 | 1 | 0 |
| Celecoxib | 1 | 1 | 0 |
| Copanlisib | 1 | 1 | 0 |
| Durvalumab | 1 | 1 | 0 |
| Entrectinib | 1 | 1 | 0 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 1 | 0 | 1 |
| Erdafitinib | 1 | 1 | 0 |
| Gefitinib | 1 | 1 | 0 |
| Ibuprofen | 1 | 1 | 0 |
| Imatinib Mesylate | 1 | 1 | 0 |
| Infigratinib | 1 | 1 | 0 |
| Iodine I-131 | 1 | 0 | 1 |
| JAK2 Inhibitor AZD1480 | 1 | 1 | 0 |
| Leucovorin | 1 | 1 | 0 |
| Linsitinib | 1 | 1 | 0 |
| NVP-AST487 | 1 | 1 | 0 |
| Pazopanib | 1 | 1 | 0 |
| PD1 Inhibitor | 1 | 1 | 0 |
| Platinum Compound | 1 | 1 | 0 |
| Porcupine Inhibitor WNT974 | 1 | 1 | 0 |
| Radioactive Iodine | 1 | 1 | 0 |
| Regorafenib | 1 | 1 | 0 |
| Ribociclib | 1 | 1 | 0 |
| Sapanisertib | 1 | 1 | 0 |
| Selumetinib | 1 | 1 | 0 |
| Sorafenib | 1 | 1 | 0 |
| Stattic | 1 | 1 | 0 |
| Tipifarnib | 1 | 1 | 0 |
| Trastuzumab | 1 | 1 | 0 |
| Tretinoin | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.